Astralis, LLC (Hercules Development Group) - ASTR
 |
|
Latest Newsletter Editions Thu, Dec 20, 2001 @ 12:12 am
Year End Update on Astralis LTD (OTC BB: ASTR) We started covering Astralis at the end of September, prior to the completion of a merger which made Astralis a public company. At the time we were very excited about the public having the opportunity to get in on the ground floor of a potential medical...
Mon, Oct 15, 2001 @ 12:10 am
ASTRALIS/ Hercules Development (OTC BB: HDVG) APPOINTS DR. JAMES J. LEYDEN, MD, CHAIRMAN OF MEDICAL ADVISORY BOARD Evidence is more compelling every day that Astralis will indeed become the dream microcap investment we originally anticipated. Today's announcement provides more evidence that this wii...
Sat, Oct 13, 2001 @ 12:10 am
Astralis/Hercules Development (OTC BB: HDVG) Announces Negotiations With European Pharmaceutical Co. News today from Astralis confirms our original suspicions that Astralis would be seeking major value added partners for both capital and technology expertise to help move the company forward. The company...
Tue, Oct 9, 2001 @ 12:10 am
How Much Does the Market Care About Treatments for Psoriasis? As mentioned in our original profile of Astralis/Hercules Development, there are 17 other drugs designed to attack the cause of Psoriasis in various stages of the FDA Approval process. The three leading candidates in Stage III clinical trials...
Sat, Oct 6, 2001 @ 12:10 am
Several days after we released our long anticipated Fall Profile on Astralis LLC it came to our attention the file size of the profile was too large for many systems. AOL zipped the file and made it impossible to read. Several other ISPs corrupted the file in other ways or simply deleted it. We have...
Click Here For More Newsletters on ASTR | |
Latest Blog Entries |
Quote Data
|
|
Business Summary
Astralis, Ltd., a development stage company, engages in the research and development of treatments for immune system disorders and skin diseases in the United States. The company’s lead product Psoraxine, a protein extract immunotherapuetic product, used for the treatment of the skin disease psoriasis, has completed phase II clinical trial. Its other product is used for the treatment of arthritis. Astralis also engages in the research and development of the technology underlying the Psoraxine for the treatment of other indications, such as eczema, leishmaniasis, and seborrheic dermatitis. The company was incorporated in 1999 and is based in Fairfield, New Jersey.
Disclosure
MarketByte, LLC has been paid a fee of $100,000 in cash and 100,000 options exercisable at $2.50 by the Investor Relations Group for publishing information on Astralis, LLC for a period of one year.
Recent News Headlines
RSS feed not found. Please remove this RSS feed or check Yahoo! Finance for more symbols.